Hello my dears,
I also continue to see potential and remain invested. And I also see a good alternative here to the popular shares such as $NOVO B (+0,18 %) Novo Nordisk.
VERTEX: MORE THAN JUST CF-THERAPIES
Vertex was long regarded as a specialist in cystic fibrosis. However, the company is rapidly developing into a broad-based biotech with a focus on gene editing and orphan diseases. The newly approved CF therapy Alyftrek is now even being reimbursed by the NHS in England. Market access is also underway in Germany, Denmark and Ireland - sales are likely to explode.
But this is just the beginning: the revolutionary CRISPR therapy PrCASGEVY for the treatment of sickle cell anemia and thalassemia shows breathtaking long-term data - 95% of patients remain crisis-free for years. The therapy has already been approved in several countries and is fully reimbursable.
For analysts it is clear: Vertex is more than just CF - it is one of the most innovative companies in the healthcare sector. No wonder that the highest analyst price target is USD 621 - a massive valuation premium compared to the current share price.
While other investors drift from hype to hype, this stock offers something rare: substance, innovation, stable cash flows and upside potential.
